Table 1.
Top 20 most abundant miRNA in sera of rheumatoid arthritis (RA) patients and control (CTR) individuals
| Human miRNAs | CTR sera* (%) | RA sera* (%) | Possible source of miRNA† |
|---|---|---|---|
| hsa‐miR‐486‐5p | 54 ± 9 | 46 ± 12 | RBC 16 |
| hsa‐miR‐92a‐3p | 14 ± 2 | 13 ± 3 | RBC, platelets, T cells, B cells, RASF 16, 17, 18 |
| hsa‐miR‐16‐5p | 4·8 ± 2·2 | 2·1 ± 1·4 | RBC, platelets, granulocytes, leucocytes 17, 18 |
| hsa‐miR‐22‐3p | 2·3 ± 0·7 | 3·8 ± 1·5 | Not known |
| hsa‐miR‐451a | 2·3 ± 0·3 | 1·4 ± 0·6 | RBC 17, 18 |
| hsa‐miR‐486‐3p | 2·2 ± 0·3 | 1·3 ± 1·5 | Granulocytes 19 |
| hsa‐miR‐191‐5p | 2·1 ± 0·4 | 2·6 ± 2·6 | Neutrophils, monocytes 20 |
| hsa‐miR‐26a‐5p | 1·4 ± 0·7 | 2·1 ± 1·7 | Platelets, T cells, B cells 17 |
| hsa‐miR‐423‐5p | 1·4 ± 0·8 | 1·8 ± 0·8 | Not known |
| hsa‐miR‐25‐3p | 0·9 ± 0·1 | 0·40 ± 0·04 | RBC, granulocytes 17 |
| hsa‐miR‐181a‐5p | 0·7 ± 0·2 | 1·0 ± 0·3 | Neutrophils, RASF 18, 21 |
| hsa‐miR‐30e‐5p | 0·7 ± 0·3 | 0·4 ± 0·1 | RASF 21 |
| hsa‐miR‐3184‐3p | 0·6 ± 0·5 | 2·1 ± 1·5 | Not known |
| hsa‐let‐7f‐5p | 0·6 ± 0·3 | 1·3 ± 1·4 | RBC, platelets, granulocytes 17 |
| hsa‐miR‐126‐5p | 0·5 ± 0·2 | 1·5 ± 1·2 | Platelets, RASF 18, 22 |
| hsa‐miR‐30d‐5p | 0·5 ± 0·2 | 0·4 ± 0·2 | Not known |
| hsa‐miR‐223‐3p | 0·5 ± 0·1 | 0·2 ± 0·2 | Granulocytes, platelets 17, 23 |
| hsa‐miR‐10b‐5p | 0·49 ± 0·07 | 2·9 ± 1·3 | RASF 18 |
| hsa‐miR‐423‐3p | 0·4 ± 0·1 | 0·3 ± 0·1 | Not known |
| hsa‐miR‐10a‐5p | 0·32 ± 0·05 | 1·7 ± 1·1 | Not known |
*Percentage of total number of miRNA reads.
†RBC, red blood cells; RASF, rheumatoid arthritis synovial fibroblasts.